Melinta Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Melinta Therapeutics, Inc.
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
Cidara Therapeutics has been given a lifeline after Johnson & Johnson’s opt-in on its universal flu prevention treatment – though the big pharma is expected to pass it onto a third party.
Clinical work on the US biotech’s drug-Fc conjugate, CD388, has been stopped by partner Janssen amid a broader company shift, but there are several paths forward for Cidara after the asset showed early promise in a Phase IIa trial.
Melinta CEO and a representative of the Infectious Diseases Society of America call on a Senate HELP subcommittee to push for passage of PASTEUR Act. Introduced in the Senate and House for the third time this year, the measure would establish a subscription model to pay drug developers upfront for certain antimicrobials.
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Rib-X Pharmaceuticals, Inc.
- Cempra, Inc. (Cempra Pharmaceuticals, Inc.)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.